Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
June 18 2024 - 8:30AM
Cerevance, a company focused on developing precision novel
therapeutics for central nervous system (CNS) diseases, will
deliver a poster presentation at the upcoming Federation of
European Neuroscience Societies (FENS) Forum 2024, taking place in
Vienna, Austria, from June 25 – 29, 2024.
Presentation details
Title: NETSseq Enhances the Understanding of
Cerebellar Transcriptomic Changes in
Ataxia-TelangiectasiaOverview:
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disease
caused by mutations in the A-T mutated gene, leading to
progressive neurological issues. Using Cerevance’s NETSseq
platform, RNA from purified cerebellar cell types of A-T and
control donors was analyzed and subsequently revealed significant
astrocyte gene expression changes related to inflammation and
immune response. These cell type-specific pathways that are altered
in disease provide insights into molecular mechanisms and potential
future drug targets.Presenter: Jenna Harvey,
PhDSession: Poster Session 06 – Section
129Session Date and Time: Friday, June 28th from
2:00 – 5:30 pm / poster presentation 2:00 – 3:30pmPoster
Number: PS06-28PM-582
About CerevanceCerevance is focused on the
development of precision treatments for central nervous system
(CNS) disorders, including chronic neurodegenerative conditions
such as Alzheimer's disease, Parkinson's disease, frontotemporal
dementia, and amyotrophic lateral sclerosis. Utilizing a large and
growing repository of over 15,000 human brain tissue samples,
Cerevance is generating an unprecedented level of expression and
epigenetic data thereby enabling the company to identify the most
promising targets for the next generation of treatments for CNS
disorders.
The company uses its proprietary Nuclear Enriched Transcript
Sort sequencing (NETSseq) platform and advanced machine learning
techniques to uncover the gene expression profiles of select cell
types to identify novel targets that are uniquely expressed in
relevant circuits affected by diseases or are altered in disease
states. With the information obtained from its research, combined
with the expertise of its team of scientists and drug developers,
Cerevance is advancing multiple therapeutics through clinical
development, with CVN424, CVN766, and CVN293 being the furthest
along in the pipeline. CVN424 is a first-in-class non-dopamine
therapy that shows promise in improving both motor and non-motor
symptoms of Parkinson's disease and may also have disease-delaying
effects. CVN766 is a potent and highly selective antagonist of the
orexin 1 receptor which may benefit various psychiatric conditions
including schizophrenia, anxiety/panic, binge eating/obesity,
substance use disorder, and Prader-Willi Syndrome. CVN293 is a
novel blocker of potassium efflux in glia, regulating the
inflammasome in individuals living with neurodegenerative
diseases.
Cerevance’s robust pipeline aims to transform the lives of
patients affected by CNS diseases.
Contacts
Cerevance: Johnna Simoes, ir@cerevance.com
Media: Andrew Mielach,
amielach@lifescicomms.com, +1-646-876-5868